Major milestone in development of novel treatment for progressive supranuclear palsy and other tau-related dementias Asceneuron SA, an emerging leader in the development of innovative small molecules for the treatment … Continue reading “Asceneuron initiates neuroimaging trial for tau modifier ASN120290”
Amsterdam, The Netherlands, November 8, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it has appointed … Continue reading “Kiadis Pharma strengthens core team with three senior appointments”
Seasoned CEO with 30 years’ experience in the healthcare industry Edinburgh, United Kingdom – 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular imaging company, today announces the appointment … Continue reading “Edinburgh Molecular Imaging Appoints Bernhard Sixt as new Chief Executive Officer”
Amsterdam, The Netherlands, November 7, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces two data presentations at … Continue reading “Kiadis Pharma announces abstracts and presentations for the 60th American Society of Hematology (ASH) Annual Meeting”
Phase 1 data show favourable safety profile Data support further development of AP30663 for cardioversion therapy COPENHAGEN, Denmark — 5 November 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech … Continue reading “Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation”
Embark was first incubated by Novo Seeds and funded through the pre-seed grant programme of the Novo Nordisk Foundation in 2016 Embark co-founder and CEO, Casper Tind Hansen, serves as … Continue reading “Novo Seeds incubatee Embark Biotech enters collaboration with Novo Nordisk to discover novel therapeutics for obesity and metabolic disease”
Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology currently focused on sexual health … Continue reading “Futura Medical Announces First Patient Enrolled in European Phase 3 study of MED2002 for the Treatment of Erectile Dysfunction”
LONDON, 30 October 2018: Arix Bioscience plc (“Arix”) (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that Aura Biosciences (“Aura”), a leader … Continue reading “Aura Biosciences reports positive Phase 1b/2 clinical data for AU-011”
Edinburgh Molecular Imaging Ltd (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces the appointment of Roy Davis as non-executive Chairman with immediate effect. John Jeans, … Continue reading “Edinburgh Molecular Imaging Ltd Appoints New Chairman”
– Novo Seeds invests €12.5 million becoming largest shareholder – Galecto Biotech was first inclubated by Novo Seeds and funded through the pre-seed grant programme of the Novo Nordisk Foundation … Continue reading “Novo Seeds Portfolio Company Galecto Biotech Raises €79 Million in Series C Financing”
Awarded a grant for vaccine development by the Bill & Melinda Gates Foundation Turku, Finland – 24 October 2018: DelSiTech Ltd, a Finnish drug delivery and drug development company, today … Continue reading “DelSiTech Ltd Receives Funding for the Stabilization of Viral Vaccines”
Keith Martin to retire as CEO, continue as Non-Executive Director Hayley French appointed COO and interim CEO HASSELT, Belgium, and CHEPSTOW, UK, 24 October 2018 – Apitope, a clinical stage … Continue reading “Apitope Announces Management Changes”
MUNICH and FRANKFURT, Germany, September 18, 2018 /PRNewswire/ — Pioneering project will enable start-ups to accelerate time to market for innovative health-related products and services aescuvest and EIT Health announce … Continue reading “aescuvest and EIT Health Launch First Pan-European Equity Crowdfunding Platform for Healthcare”
CALGARY, Alberta and SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors … Continue reading “Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care”
LONDON, 12 September 2018: Arix Bioscience plc (“Arix”) (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announced that industry veteran Arthur Pappas has been appointed … Continue reading “ARIX Bioscience Plc Announces Board Changes, Appointment of Arthur Pappas to the Board of Directors, David U’Prichard to retire from Board”
CALGARY, Alberta and SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors … Continue reading “Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program”
Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that it has raised an additional €4 million of funding from Vesalius Biocapital … Continue reading “Vesalius Biocapital III Partners joins Forendo Pharma Investor Syndicate”
Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced that Dr. Michael Schaeffer has been appointed to the … Continue reading “Probiodrug Appoints Dr. Michael Schaeffer as Executive Vice President of Business and Strategy”
Azeria Therapeutics Limited, a newly formed drug discovery company, today announced that it has successfully raised £4 million in Series A fundraising from the £70 million CRT Pioneer Fund, managed … Continue reading “Azeria Therapeutics, the world’s first pioneer factor drug discovery company, announces Series A investment from Sixth Element Capital”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2018 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com